Affiliation:
1. 1 Department of Transfusion Medicine and Transplantation , Biology University Hospital Centre Zagreb Zagreb , Croatia
2. 2 University of Zagreb Faculty of Pharmacy and Biochemistry , Zagreb , Croatia
3. 3 University of Zagreb School of Medicine , Zagreb , Croatia
Abstract
Abstract
Although the use of cryoprotectant dimethyl sulfoxide (DMSO) is the gold standard in cryopreservation of hematopoietic stem cells, it is well known that it has a negative effect on cell viability. The aim of this prospective study was to examine how the length of post-thaw exposure to DMSO affects the cell viability and stability of peripheral blood stem cell (PBSC) samples. Additionally, the effects of donor type and pre-cryopreservation storage time on post-thaw viability during the stability study were evaluated. In 30 autologous and 30 allogeneic PBSC samples viable CD34+, CD14+, CD19+, CD16+/56+, and CD3+ cells were determined immediately after thawing, and one-and three-hours post-thaw.
Analysis of the absolute count of viable cells in thawed samples showed a significant difference between all measurement points for CD34+ (p < 0.001), CD14+ (p < 0.001), and CD19+ cells (p < 0.001). No significant differences were observed for post-thaw stability of allogeneic samples analysed between products stored before cryopreservation ≥ 24 hours (N = 20), and those stored < 24 hours (N = 10), except for viable CD3+/CD4+ cells after three hours post-thaw (p = 0.028). In conclusion, DMSO had different effects on leukocyte subpopulations in cryopre-served PBSC samples. The type of donors and the length of storage before cryopreservation did not affect the post-thaw stability of cryopreserved PBSC samples.
Subject
Pharmaceutical Science,Pharmacology,General Medicine
Reference21 articles.
1. FACT-JACIE International Standards for Hematopoietic Cellular Therapy. Product Collection, Processing, and Administration. Eight edition. https://www.ebmt.org/jacie-standards; last access date January 20, 2023.
2. P. Wuchter, Processing, Cryopreserving and Controlling the Quality of HSCs, in The EBMT Handbook Hematopoietic Stem Cell Transplantation and Cellular Therapies (Eds. E. Carreras, C. Dufour, M. Mohtyand, N. Krögel), European Society for Blood and Marrow Transplantation 2019, pp.127–130.
3. European Society for Blood and Marrow Transplantation. Coronavirus disease COVID-19: EBMT recommendations update April 21, 2020; https://www.ebmt.org/sites/default/files/2020-04/EBMT_COVID-19-guidelines_v.7.1%282020-04-21%29.pdf; last access date January 12, 2023.
4. National Marrow Donor Program: BeTheMatch. Donor Product Cryopreservation: updated March 23, 2020; https://www.ebmt.org/sites/default/files/2020-04/EBMT_COVID-19-guidelines_v.7.1%282020-04-21%29.pdf; last access date January 12, 2023.
5. K. Hornberger, G. Yu, D. McKenna and A. Hubel, Cryopreservation of hematopoietic stem cells: Emerging assays, cryoprotectant agents, and technology to improve outcomes, Transfus. Med. Hemother. 46(3) (2019) 188–196; https://doi.org/10.1159/000496068